Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

cetuximab

cetuximab
  • Restricted Anti-Neoplastic Formulary
  • Restricted Erbitux --> Restricted to outpatient oncology and inpatient head or neck cancer being treated with radiation therapy and unable to receive CISplatin.
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Erbitux SOLUTION, INTRAVENOUS 2 mg/mL      
VIEW MORE Antineoplastic Agents
CLASS
100000
Comments:

 

Restricted to outpatient oncology and inpatient head or neck cancer being treated with radiation therapy and unable to receive CISplatin. For metastatic colorectal cancer, use is limited to KRAS wild type, EGFR expressing cases.

Reviewed: June 22, 2005, and 24 April 2018 (Erbitux)

Last updated: Apr. 11, 2024






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved